Environmental air monitoring in international airports: A novel approach for enhanced pathogen surveillance

Dawn Gratalo[1], Cindy R. Friedman*[2], Valerie J. Morley[1], Xueting Qiu[1,4], Ian Ruskey[2], Andrew P. Rothstein[1], Patrick B. Tiburcio[3], Casandra W. Philipson[1,4], Thomas W.S. Aichele[1,4], Stephen M. Bart[2,4], Dustin Jaynes[5], Birgitte B. Simen[1], Shelby L O'Connor[3], David H. O'Connor*[3]

[1] Ginkgo Biosecurity, 27 Drydock Ave 8th Floor, Boston, MA, USA
[2] Division of Global Migration Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
[3] Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI USA
[4] Former Affiliation
[5] Department of Public Safety, Dallas/Fort Worth International Airport, Texas, USA

Corresponding authors email: ccf6@cdc.gov and dhoconno@wisc.edu

Abstract

Early detection of outbreaks and emerging pathogens is critical for public health and global biosecurity. Airports, as major international travel hubs with dense, enclosed populations, are high-risk settings for disease transmission and potential pathogen introduction. The U.S. Centers for Disease Control and Prevention, in collaboration with Ginkgo Biosecurity and the University of Wisconsin–Madison, implemented air monitoring for pathogen surveillance in congregate areas at four U.S. international airports. From October 2023 to August 2024, SARS-CoV-2 was detected by PCR in 98.3% of air samples and influenza A in 17.2%. These results correlated with positivity trends from other sample modalities, including aviation wastewater, traveler nasal swabs, and national clinical surveillance data. Targeted amplicon sequencing of SARS-CoV-2 from air samples correlated with contemporaneous lineages in wastewater collected and sequenced from the same airports. Metagenomic enrichment sequencing detected 30 viral species and recovered high-quality genomes for SARS-CoV-2, influenza, bocavirus, and seasonal coronaviruses. Together, these findings demonstrate that air

sampling is a complementary surveillance modality to aviation wastewater for early pathogen detection at ports of entry.

Key Words: Air monitoring, pathogen surveillance, airports, wastewater, SARS-CoV-2, influenza, metagenomic sequencing, environmental surveillance, pandemic preparedness, biosecurity

Introduction

Epidemic and pandemic preparedness relies heavily on robust and adaptive surveillance systems capable of early pathogen detection. Global travel hubs, particularly international airports, are critical interfaces for the introduction and spread of emerging and re-emerging pathogens due to their dense, transient populations and high interconnectedness.[1–4] Detecting pathogens and identifying new variants in airports is especially important, as illustrated during the COVID-19 pandemic, which underscored the urgent need for near real-time genomic surveillance strategies.[5] While testing of nasal swabs from arriving travelers provides one modality for monitoring, the process can be labor-intensive and relies on traveler willingness to participate.

Environmental surveillance has emerged as a non-invasive approach to characterize pathogens circulating in communities. Wastewater surveillance, including community and aviation wastewater, has demonstrated utility in tracking both the prevalence and genetic diversity of viruses such as SARS-CoV-2.[6–8] Air monitoring serves as a complementary public health surveillance tool, enabling the collection of pathogenic genetic material shed by individuals. This approach is particularly effective for capturing respiratory pathogens from diverse populations, including asymptomatic or pre-symptomatic individuals who might not otherwise engage with clinical testing or contribute to accessible wastewater systems. Studies have shown the effectiveness of air sampling in multiple congregate settings. In hospitals, airborne

pathogen detection has correlated strongly with clinical data [9], and airborne pathogen genetic material has also been detected in other communal spaces such as schools.[10–12] As a scalable and cost-effective surveillance option, non-invasive air monitoring is particularly relevant for high-traffic environments, such as international airports, that serve as gateways into communities.

While PCR-based detection confirms the presence of pathogen genetic material, genomic sequencing is essential for identifying specific lineages, tracking variant evolution, and informing the development of diagnostics and therapeutics.[13–16] However, obtaining high-quality genomic data from air samples presents challenges due to low biomass and nucleic acid degradation, especially for RNA viruses.[17] Advanced sequencing methodologies are therefore crucial. Targeted amplicon sequencing offers high sensitivity but is limited to a narrow range of pathogens, while metagenomic approaches provide an agnostic view but often lack sensitivity for low-abundance targets. Metagenomic enrichment sequencing represents a promising strategy to improve both breadth and sensitivity by enriching viral nucleic acids prior to sequencing.[9,18]

In this study, air monitoring surveillance was implemented in congregate areas of four major U.S. international airports to assess the feasibility of detection of SARS-CoV-2 and Influenza A virus genetic material in an international airport setting; evaluate the effectiveness of sequencing methods for viral genome characterization from these air samples; and determine the complementary value of air monitoring within existing pathogen surveillance frameworks. This study explores the development of air monitoring as a proactive biosecurity system, to enhance our capacity for early threat identification at the critical intersection of global travel and community health.

Methods

ThermoFisher AerosolSense™ active air samplers were placed in congregate areas adjacent to customs and immigration inspection areas at San Francisco International Airport, California (SFO); Newark Liberty International Airport, New Jersey (EWR); Washington Dulles International Airport, Virginia (IAD); and Dallas/Fort Worth International Airport, Texas (DFW). Samples were collected from October 18, 2023–August 27, 2024, at SFO, EWR, and IAD, and from February 7–August 14, 2024, at DFW. At SFO, a second sampler was added on June 3, 2024 (denoted by the orange star in Figure 1), and both instruments operated until study end. Each ThermoFisher AerosolSense™ unit collected samples for 10 hours per day. ThermoFisher AerosolSense cartridges containing polyurethane foam substrates were removed from each air sampling machine after approximately 20 hours of use Monday through Thursday and after 30 hours of use Friday through Sunday.

Cartridges were couriered to UW-Madison for extraction and qRT-PCR analyses. All results were linked to airport and collection date via unique barcodes. Each substrate was submerged in 500 µL of 1X phosphate-buffered saline (PBS) and vortexed. RNA was extracted from 300 µL of eluate using a Maxwell® RSC Viral Total Nucleic Acid Purification Kit (Promega). Molecular detection of SARS-CoV-2, influenza A, and RNase P is described in Supplemental Methods. From October 18, 2023–March 12, 2024, qRT-PCR reactions were performed on a LightCycler® 480 System (Roche) using a TaqMan Fast Virus 1-Step Kit (ThermoFisher) with CDC-modified assays targeting the SARS-CoV-2 nucleocapsid gene (N1, N2) and the influenza A M gene, in duplicate.[19] Pathogen results were categorized as positive if both Ct values were <40, inconclusive if only one Ct <40, and negative if neither Ct <40. This categorization applied to both SARS-CoV-2 and influenza A assays. On March 12, 2024, the thermocycler was changed to accommodate a multiplex assay (denoted by the red star in Figure 1). For each

cartridge, a single multiplex assay measuring the SARS-CoV-2 N1 and influenza A M targets were performed. The human RNase P gene served as an internal control; samples negative for RNase P were excluded from analysis.

For targeted SARS-CoV-2 sequencing, purified total nucleic acid (TNA) was amplified by multiplex RT-PCR (NEB LunaScript Multiplex One-Step RT-PCR) using the ARTIC primer set (IDT ARTIC V5.3.2 NCOV-2019 Panel).[20] Amplicons were pooled, and libraries prepared with a modified Illumina DNA Prep protocol. Libraries were sequenced on an Illumina NovaSeq 6000, targeting ~1.5 million paired-end 150 bp reads per sample.

For metagenomic enrichment sequencing, input to library prep was either total nucleic acid (TNA) or cleaned and concentrated TNA (Zymo Research, Irvine, CA). Extracts were prepared for enrichment using the Illumina RNA for Enrichment Sample Preparation Kit with the Respiratory Virus Oligo Panel, following the manufacturer's protocol (Illumina, San Diego, CA). Libraries were validated for size and adapter dimer removal on an Agilent TapeStation 4200 D1000 High Sensitivity assay, quantified and normalized using the dsDNA High Sensitivity Assay on a Qubit 3.0 (Life Technologies, Carlsbad, CA), denatured/diluted, and pooled per manufacturer's instructions. Pooled libraries were sequenced on the Illumina NovaSeq 6000 (v1.5 chemistry) to a target depth of ~7 million paired-end 150 bp reads per sample. Bioinformatics pipelines and analysis details are provided in Supplemental Data.

For aviation wastewater and traveler nasal swabs, data were generated from samples collected and processed as part of the Traveler Genomic Surveillance (TGS) program from October 18th, 2023-August 27th, 2024. Aviation wastewater was collected from arriving international aircraft at IAD (N=330), and SFO wastewater was collected from triturators (N=161).Triturators are collection points where waste from multiple flights is discharged and homogenized before

being combined with airport terminal wastewater. Travelers volunteered to self-collect anterior nasal swabs on arrival at IAD (N = 16,004) and SFO (N = 30,182). Wastewater samples were concentrated with Nanotrap Microbiome Particles and extracted using a MagMAX Microbiome Ultra Nucleic Acid Isolation Kit (Thermo Fisher). Extracts were tested by digital PCR for SARS-CoV-2 and influenza A/B (Qiagen), and SARS-CoV-2 sequencing was performed as described above.

Upon laboratory receipt, nasal swab samples were heat-inactivated at 70°C for 30 minutes, and total nucleic acids extracted using the MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit (Thermo Fisher). Extracts were tested by qPCR using the TrueMark™ SARS-CoV-2/Flu A/Flu B/RSV Select Panel on a QuantStudio™ 5 qPCR instrument (Thermo Fisher). SARS-CoV-2 sequencing was performed as described above.

This activity was reviewed by CDC, deemed not human subjects research, and conducted in accordance with applicable federal law and CDC policy (45 CFR part 46; 21 CFR part 56).

Results

During October 18, 2023–August 27, 2024, 463 air monitoring samples were collected and tested by qRT-PCR from four international airports (Figure 1). The RNase P control was positive for 460 of 463 samples (99.1%). Among these 460 RNAseP+ samples, SARS-CoV-2 was detected in 452 (98.3%). Of the remaining eight samples, five were negative and three were inconclusive. When stratified by airport, positive SARS-CoV-2 detections were: SFO: 137 (97.9%), EWR: 124 (98.4%), IAD: 118 (97.5%), and DFW: 73 (100%) (Figure 1).

Among the 460 RNAseP+ samples, 79 were positive for influenza A (17.2%), while 327 were negative and 54 were inconclusive. By airport, influenza A detections were: SFO: 36 (25.7%), EWR: 20 (15.9%), IAD: 10 (8.3%), and DFW: 13 (17.8%). Positive detections of influenza A

occurred weekly between January 1 and March 18, 2024, then occurred sporadically through April 22, 2024, after which no further positives were observed (Figure 1).

To compare SARS-CoV-2 and influenza A trends across modalities, data from two airports (SFO and IAD) with overlapping aviation wastewater, airport air, and traveler nasal swab collections were analyzed. Publicly available U.S. clinical respiratory specimen data (https://www.cdc.gov/nrevss/php/dashboard/index.html) were also included for comparison. Airport air and aviation wastewater had higher weekly positivity rates for SARS-CoV-2 and influenza A than traveler nasal swabs and national clinical samples, reflecting expected differences between population-level (air, wastewater) and individual-level (nasal swab) sampling (Figure 2A). SARS-CoV-2 positivity from air sampling correlated significantly with aviation wastewater (Figure 2B; Pearson's $p < 0.001$), traveler nasal swabs (Figure 2C; $p = 0.04$), and national surveillance (Figure 2D; $p < 0.001$). Influenza A positivity from air sampling also correlated significantly with aviation wastewater (Figure 2E; $p = 0.002$), traveler nasal swabs (Figure 2F; $p < 0.001$), and national surveillance (Figure 2G; $p < 0.001$).

Of the 460 RNAseP+ air samples, 338 were tested for SARS-CoV-2 sequences; 216 (64%) yielded high-quality genomes (≥70% genome coverage), and 167 (77%) of those contained multiple lineages. SARS-CoV-2 variant trends in air and aviation wastewater samples were similar at both airports (Figure 3A, 3B). Between January 29 and August 26, 2024, both sample types showed a decline in Omicron JN.1 and an increase in KP.2/KP.3, consistent with contemporaneous national trends.[21] KP.x variants were detected in aviation wastewater earlier than air samples (42 days earlier for KP.2, 41 days earlier for KP.3).

Metagenomic sequencing with hybrid capture enrichment for respiratory virus genomes was performed on a total of 98 air samples, split into two sequencing runs (Figure 4), using samples that did not overlap with those used for SARS-CoV-2 amplicon sequencing. In the first run

(N=52), a mean of 0.04% (95% CI [0.01%, 0.06%]) of total reads per sample mapped to virus targets. After incorporating a TNA concentration step prior to library prep, the second run (N = 46) achieved a mean of 11.8% (95% CI: 7.04 –16.5%) of reads mapping to viral genomes.

Across all samples, reads from 30 viral species were detected. The most frequent were SARS-CoV-2 (100% of samples; mean RPKM 1007, 95% CI: 351-1663), influenza A (57% of samples; mean RPKM 111, 95% CI: 62.7-159), and seasonal coronavirus HCoV-229E (45% of samples; mean RPKM 163, 95% CI: 18.9-306). Influenza B (28%), RSV A (29%), and RSV B (43%) were also detected. For influenza A, 88% (28/32) of PCR-positive samples had sequencing reads mapping to the genome. An additional 27 samples with influenza A reads were PCR-inconclusive (n = 12) or negative (n = 15).

In addition to revealing viral diversity, enrichment sequencing yielded high-quality genomes (≥70% reference coverage at 10× depth) in 4% (2/52) of samples from the first run and 35% (16/46) of samples from the optimized second run. Overall, 25 high-quality genomes were recovered from 98 samples, including SARS-CoV-2 (n = 11), influenza A (n = 4), bocavirus (n = 2), WU polyomavirus (n = 5), and seasonal coronaviruses (n = 3).

Discussion

The findings of this project support air sampling as a viable option for pathogen surveillance in airports. The data suggest that i) air sampling can serve as a layered or alternative surveillance option, ii) targeted genomic sequencing from air samples provides the resolution needed to identify important variants, and iii) metagenomic enrichment sequencing enables multipathogen detection from air. To our knowledge, this is the first study to demonstrate a correlation between respiratory viruses detected in air samples, aviation wastewater, and nasal swabs from travelers at the same airport, as well as with national clinical respiratory data. Both air and wastewater monitoring offer valuable insights. The strong correlation in observed trends

across these two systems underscores their complementary value in a multi-layered surveillance approach, with each capturing signals from distinct yet overlapping populations.

In airport environments, air monitoring offers real-time, passive surveillance, serving as a crucial interface between emerging threats and community spread. In this project SARS-CoV-2 RNA was detected in nearly all samples (98.3%) compared with 17.2% for influenza A. Influenza A detections were concentrated in the winter months and mirrored national clinical data trends from the 2023-2024 influenza season. The near ubiquitous detection of SARS-CoV-2 underscores the value of genomic sequencing for tracking new variant introductions of highly prevalent pathogens. Sequencing in our study showed JN.1 as the predominant lineage, followed by increases in KP.2 and KP.3 sublineages, consistent with national surveillance data.[21]

Genomic sequencing of air sampling has been shown as a highly effective method for pathogen surveillance,[11,12,22] but methodological considerations remain. Targeted amplicon methods, commonly applied to SARS-CoV-2, have excellent sensitivity, which is valuable for identifying circulating lineages, but interrogate only a narrow set of pathogens. Untargeted metagenomic sequencing captures a broader diversity of pathogens; but the low amount of starting genomic material in air samples presents a technical challenge. Here, we addressed this challenge with hybrid-capture enrichment sequencing, enabling detection of a broad panel of pathogens despite the limitations of input material. Our results show that metagenomic enrichment sequencing increased mapped reads and improved recovery of high-quality genomes from air samples. This approach also detected more influenza A material than PCR, though this may reflect limitations of the specific PCR assay (suggested by the number of inconclusive results) as well as the low sequencing thresholds applied in our study (any read counted as detection). Future work should focus on improving sensitivity through better air

sample collection, nucleic acid recovery, and sequencing efficiency to expand the ability to detect less abundant pathogens. In parallel, defining clear detection limits would strengthen confidence in genomic data, especially when only limited sequences are recovered.

Air monitoring provides a non-invasive means to track pathogen presence and spread in specific environments. It complements clinical surveillance by capturing signals from large numbers of asymptomatic or mildly symptomatic individuals who would otherwise go undetected. By offering insights into pathogen dynamics, air monitoring can support early threat detection and enable timely public health interventions, even before clinical cases are widely reported. It has been applied in schools[12] and proposed for long-term care facilities and workplace settings. Air monitoring may also be particularly valuable where wastewater surveillance is impractical, such as in maritime environments, where access to wastewater is limited and where dense populations, close contact, and frequent embarkation/disembarkation increase both transmission risk and the potential for pathogen introduction.[23]

In the future, indoor air detection of viral pathogens in airports or other international ports of entry could become a cornerstone of proactive pandemic preparedness. Continuous or intermittent air sampling, coupled with rapid detection technologies, could provide real-time insights into circulating pathogens. Upon detection of elevated viral loads, targeted mitigation measures, such as increased ventilation[24], air purification[25], public health messaging, or resource allocation, could be swiftly launched. This proactive approach, moving beyond reactive clinical case identification, could significantly reduce the risk of disease spread and enhance global health security. Our study highlights air sampling as a feasible, non-invasive strategy for pathogen surveillance. Integrating airport air sampling into existing frameworks can enhance the ability to identify emerging threats and build more resilient, proactive biosecurity systems to address current and future challenges.

Declaration of Competing Interests

DG,BBS,AR,VJM,CWP,XQ, and TWSA were employed by Ginkgo Bioworks at the time of the study and received Ginkgo Bioworks stocks. D.H.O. received support for this project from Inkfish, Heart of Racing, and the University of Wisconsin-Madison Institute for Clinical and Translational Research's Pilot Award program. This work was also supported in part by awards to D.H.O. from the Wisconsin Department of Health Services (435100-A24-ELCProjE) and the US Centers for Disease Control and Prevention (75D30122C15355). D.H.O. and S.L.O. are managing partners of Pathogenuity LLC, a consultancy that advises on environmental monitoring issues. S.L.O.'s work on this project was funded by Inkfish and Heart of Racing.

The funders played no role in the drafting of this manuscript. The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this manuscript.

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.

Author contributions
DG, CRF, SLO, and DHO contributed to ideas, work, writing, accountability and stewardship. CWP contributed to ideas, work, and stewardship. AR and VJM contributed to work, writing and accountability. BBS contributed to writing, accountability, and stewardship. XQ and PBT contributed to work. TWSA contributed to ideas and work. SB and DJ contributed to work. IR contributed to ideas and accountability.

Acknowledgements
We are deeply grateful to our partners at XpresCheck for sample collection and support. We thank Amy Schierhorn for program support. We thank Bo Reese and staff at Center for

Genome Innovation, Institute for Systems Genomics, University of Connecticut for sequencing support. We thank the CDC Port Health Station staff including Steve Burchell, Erica Sison, Jonathan Georges, Helen MacGregor, Kara Adams, and Ayianna Kennerly. We also thank Miranda Stauss and Eli O'Connor in the O'Connor Labs for cartridge tracking.

Data Availability

All raw sequencing data is available in the NCBI sequence read archive (SRA) database under CDC's Traveler-Based Genomic Surveillance Program BioProject PRJNA989177. All other code used to generate figures is available at https://github.com/concentricbyginkgo/TGS-AirMonitoring-Supplemental.

References

1.   Tegally, H. *et al.* Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern. *Cell* **186**, 3277-3290.e16 (2023).
2.   Baker, R. E. *et al.* Infectious disease in an era of global change. *Nat Rev Microbiol* **20**, 193–205 (2022).
3.   Mangili, A. & Gendreau, M. A. Transmission of infectious diseases during commercial air travel. *The Lancet* **365**, 989–996 (2005).
4.   Wilder-Smith, A. COVID-19 in comparison with other emerging viral diseases: risk of geographic spread via travel. *Trop Dis Travel Med Vaccines* **7**, 3 (2021).
5.   Wegrzyn, R. D. *et al.* Early Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Using Traveler-based Genomic Surveillance at 4 US Airports, September 2021–January 2022. *Clin Infect Dis* **76**, e540–e543 (2023).
6.   Ahmed, W. *et al.* Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater. *Science of The Total Environment* **820**, 153171 (2022).
7.   Morfino, R. C. Notes from the Field: Aircraft Wastewater Surveillance for Early Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City, August–September 2022. *MMWR Morb Mortal Wkly Rep* **72**, (2023).
8.   Agrawal, S. *et al.* Genome Sequencing of Wastewater Confirms the Arrival of the SARS-CoV-2 Omicron Variant at Frankfurt Airport but Limited Spread in the City of Frankfurt, Germany, in November 2021. *Microbiology Resource Announcements* **11**, e01229-21 (2022).
9.   Bobrovska, S. *et al.* Hospital air sampling enables surveillance of respiratory virus infections and genomes. *Science of The Total Environment* **977**, 179346 (2025).
10.   Minor, N. R. *et al.* Metagenomic sequencing detects human respiratory and enteric viruses in air samples collected from congregate settings. *Scientific Reports* **13**, 21398 (2023).

11.   Ramuta, M. D. *et al.* SARS-CoV-2 and other respiratory pathogens are detected in continuous air samples from congregate settings. *Nat Commun* **13**, 4717 (2022).

12.   Temte, J. *et al.* Four Methods for Monitoring SARS-CoV-2 and Influenza A Virus Activity in Schools. *JAMA Netw Open* **6**, e2346329 (2023).

13.   Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral genome sequencing. *Nat Rev Microbiol* **15**, 183–192 (2017).

14.   Hilt, E. E. & Ferrieri, P. Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases. *Genes* **13**, 1566 (2022).

15.   Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and challenges in virus genomic epidemiology. *Trends in Parasitology* **37**, 1038–1049 (2021).

16.   Quainoo, S. *et al.* Correction for Quainoo et al., "Whole-Genome Sequencing of Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis". *Clinical Microbiology Reviews* **31**, 10.1128/cmr.00082-17 (2017).

17.   Behzad, H., Gojobori, T. & Mineta, K. Challenges and Opportunities of Airborne Metagenomics. *Genome Biology and Evolution* **7**, 1216–1226 (2015).

18.   Quek, Z. B. R. & Ng, S. H. Hybrid-Capture Target Enrichment in Human Pathogens: Identification, Evolution, Biosurveillance, and Genomic Epidemiology. *Pathogens* **13**, 275 (2024).

19.   Lu, X. *et al.* US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2608.201246.

20.   Quick, J. nCoV-2019 sequencing protocol. (2020).

21.   Ma, K. C. *et al.* Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024. *MMWR Morb Mortal Wkly Rep* **73**, 938–945 (2024).

22.   Raymenants, J. *et al.* Indoor air surveillance and factors associated with respiratory pathogen detection in community settings in Belgium. *Nat Commun* **14**, 1332 (2023).

23.   Kumar, P. *et al.* Airborne pathogen monitoring and dispersion modelling on passenger ships: A review. *Science of The Total Environment* **980**, 179571 (2025).

24.   Faulkner, C. A. *et al.* Comparison of effectiveness and energy use of airborne pathogen mitigation measures to meet clean air targets in a prototypical office building. *Building and Environment* **257**, 111466 (2024).

25.   Azimi, P. & Stephens, B. HVAC filtration for controlling infectious airborne disease transmission in indoor environments: Predicting risk reductions and operational costs. *Build Environ* **70**, 150–160 (2013).

Figure 1: PCR detection from airport air samples. Positive qRT-PCR detections and Ct values of Influenza A, SARS-CoV-2, and RNase P controls captured by ambient air monitoring surveillance from congregate areas in 4 U.S. international airports, October 2023–August 2024. The red star indicates a change of assay; quantitative results before and after this point cannot be directly compared. The orange star indicates when a second sampler was added to the San Francisco airport.

Figure 2: Respiratory virus positivity trends for airport air, aviation wastewater, and traveler nasal swab surveillance. As part of the CDC TGS program, two international airports (SFO and IAD) had overlapping collections for aviation wastewater, airport air, and individual traveler nasal swabs from October 18, 2023-August 27, 2024. Data from these two airports

were used to compare virus positivity trends across surveillance modalities. Publicly available data from USA respiratory virus clinical testing (CDC NREVSS) was also included for comparison to national trends. A) Percent positivity for influenza A and SARS-CoV-2 PCR detection compared across surveillance modalities. B-D) Correlation between airport air PCR Ct values for SARS-CoV-2 and (B) aviation wastewater percent PCR positivity, (C) traveler nasal percent PCR positivity, and (D) NREVSS clinical percent positivity. Because percent positivity was near 100% for SARS-CoV-2 in airport air and aviation wastewater samples, PCR values (Ct for qPCR; copies/mL for dPCR) were analyzed instead of percent positivity. E-G) Correlation between airport air weekly percent positivity for influenza A and (E) aviation wastewater percent positivity, (F) traveler nasal swab percent positivity, and (G) NREVSS clinical percent positivity.

Figure 3: SARS-CoV-2 genomes from wastewater and air samples at two airports (SFO and IAD), samples collected from Jan 29, 2024 to Aug 26, 2024. Genomic sequencing data from A. aviation wastewater (SFO-triturator, IAD-aircraft) and B. Air samples. Aviation wastewater includes both triturator from SFO, which is the aggregate of aircraft lavatory waste and aircraft wastewater from IAD, which is direct from single aircraft lavatory waste.

Figure 4: Detection of viral genomes from air samples by metagenomic enrichment sequencing. Nucleic acid extracted from air filters (N=98) collected from three airports (EWR, IAD, SFO) was sequenced using the Illumina Respiratory Viral Oligo hybrid-capture panel for respiratory viruses. Samples to the right of the red line indicate when an RNA concentration step was added to the sequencing library prep protocol. The heatmap shows the normalized abundance of reads mapping to each viral target (RPKM = reads per kilobase per million reads). Each white heatmap column represents a single air sample, and detected viruses are listed on the y-axis. Gray columns represent dates where no sample was collected at the listed airport.